Conditions: Leukemia Lymphoma Myelodysplastic Syndrome
Keywords: Stem Cell Transplant Allogeneic Transplant Donors
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 35
Healthy volunteers: no

Brief summary:
A common problem after stem cell transplant is graft-versus-host-disease (GVHD). GVHD is a complication of transplantation where the donor graft attacks and damages some of your tissues. After stem cell transplant, all patients receive prophylactic medications against GVHD.

In this research study, we are studying the safety and effectiveness of a bortezomib based GVHD prophylaxic drug combination in participants after myeloablative allogeneic stem call transplantation from a matched unrelated donor, mismatched related or unrelated donor.

Detailed description:
Before your transplant you will receive conditioning therapy with fludarabine and busulfan given 7, 6, 5, and 4 days before your transplant. On day 0, you will receive selected blood cells taken from your sibling or unrelated donor.

You will receive 3 drugs for your GVHD prophylaxis:

Tacrolimus will be started 3 days before your transplant. It will be given intravenously and later by mouth. You will continue to take tacrolimus for 3 to 6 months after transplant.

Methotrexate will be given intravenously 1, 3, 6 and 11 days after your transplant.

Bortezomib will be given intravenously 1, 4, and 7 days after your transplant. On days 1, 4, 7, 30 and 3, 6 and 12 months after your transplant you will have a physical exam, blood work, and be asked to complete a questionnaire.

Arms:
arm 1: Drug: Bortezomib. Other Names: Velcade. Bortezomib 1.3 mg/m\^2 IV

Drug: Tacrolimus. Tacrolimus 0.05 mg/kg PO bid

Drug: Methotrexate. Methotrexate 15 mg/m\^2 IV

Interventions: intervention 1: Bortezomib intervention 2: Tacrolimus intervention 3: Methotrexate
Intervention descriptions: intervention 1: Bortezomib 1.3 mg/m\^2 IV intervention 2: Tacrolimus 0.05 mg/kg PO bid intervention 3: Methotrexate 15 mg/m\^2 IV

Protocol document: